Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Says Pfizer’s PCSK9 Phase III Plan Will Boost The New Drug Class

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi CEO Christopher Viehbacher seemed unperturbed by Pfizer’s ambitious PCSK9 Phase III development program, saying it will increase interest in the new drug class.

You may also be interested in...



Sanofi Channel Stuffing In Brazil?

Sanofi CEO Chris Viehbacher showed clear signs of disappointment during the company’s earnings call, admitting emerging markets underperformed, and revealing a debacle in Brazil that appears to be channel stuffing.

Freshly Funded ImCheck Goes After Gamma Delta T-Cells

ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.

Novartis Enters ‘Transformational’ Cloud Computing Pact With Amazon

Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.

Topics

Related Companies

UsernamePublicRestriction

Register

PS074975

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel